Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Vertex Pharmaceuticals Incorporated

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Vertex Pharmaceuticals (VRTX) and Green Thumb Indu...

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Green Thumb Industries (OtherGTBIF)

Anthropic, the artificial intelligence (AI) firm behind Claude, has just bought a small biotech startup called Coefficient Bio for about $400 milli...

Anthropic Finalizes $400 Million Takeover of AI Startup Coefficient Bio

Vertex Pharmaceuticals ( ($VRTX) ) has issued an update. Vertex Pharmaceuticals has completed the rolling submission of a Biologics License Applica...

Vertex Advances FDA Filing for IgA Nephropathy Therapy

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Neurogene (NGNE), Vertex Pharmaceuticals (VRTX) an...

Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE), Vertex Pharmaceuticals (VRTX) and Sarepta Therapeutics (SRPT)

Analysts are intrested in these 5 stocks: ( ($TTD) ), ( ($OCGN) ), ( ($STZ) ), ( ($VRTX) ) and ( ($LCID) ). Here is a breakdown of their recent


TTD, OCGN, STZ, VRTX, LCID Trending With Analysts

RBC Capital analyst Brian Abrahams maintained a Buy rating on Vertex Pharmaceuticals today and set a price target of $541.00. Abrahams covers the H...

RBC Capital Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Beam Therapeutics (BEAM – Research Report), Pelthos ...

Analysts Are Bullish on These Healthcare Stocks: Beam Therapeutics (BEAM), Pelthos Therapeutics (PTHS)

TipRanks’ Trending Stocks tool allows users to filter activity over the past 30 days, seven days, or even the last 72 hours to see which stocks are...

3 Best Trending Stocks, According to Analysts – 3/12/2026

In a report released today, Whitney Ijem from Canaccord Genuity maintained a Hold rating on Vertex Pharmaceuticals, with a price target of $441.00....

Canaccord Genuity Keeps Their Hold Rating on Vertex Pharmaceuticals (VRTX)

Investors will find all the hottest earnings, analysts, and acquisition news worth reading about today in the TipRanks wrap-up for Tuesday.


Morning News Wrap-Up 3/10/26: Tuesday’s Biggest Stock Market Stories!

The biotech concern has found success in treating cystic fibrosis. 


Market Cap	$109.89B	P/E Ratio	26.34
52W High	$510.77	52W Low	$362.50
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	-30.6%	52W Position	56.0%
Overall Score	48	Value Score	60
Quality Score	68	Technical Score	18

EPS Current Est	$16.91	EPS Next Est	$19.17
EPS Growth Est	+13.4%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	VRTX	$445.49	+0.35%	635.74K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	VRTX	$445.49	+0.4%	635.74K
3
4
5
6

VRTX

VRTX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Vertex Pharmaceuticals Incorporated Data in Excel

Get Vertex Pharmaceuticals Incorporated Data in Excel